In 2018, the capacity utilization rate of China's pharmaceutical manufacturing industry in the fourth quarter was 77.0%

[market analysis of chinapharma.com] on January 21, 2019, the National Bureau of statistics issued the article "the utilization rate of national industrial capacity in the fourth quarter of 2018 is 76.0%" In the fourth quarter of 2018, the utilization rate of national industrial capacity was 76.0%, down 2.0 percentage points from the same period of last year In 2018, the utilization rate of national industrial capacity was 76.5%, down 0.5 percentage points over the previous year Among them, according to the table of industrial capacity utilization rate in the fourth quarter of 2018, the capacity utilization rate of pharmaceutical manufacturing industry in the fourth quarter was 77.0%, 3.6% lower than the same period of last year, and 77.6% lower than the whole year in 2018, 1.5% lower than the previous year The note shows that capacity utilization refers to the ratio of actual output to production capacity (both measured in value) The actual output of the enterprise refers to the total industrial output value of the enterprise in the reporting period; the production capacity of the enterprise refers to the product output that the enterprise can achieve and can maintain for a long time when the production equipment (machinery) maintains normal operation under the condition that the supply of labor, raw materials, fuel, transportation, etc is guaranteed during the reporting period According to the definition, pharmaceutical manufacturing industry refers to the process that raw materials become new pharmaceutical products after physical or chemical changes, including the manufacturing of traditional Chinese and Western medicine, veterinary medicine also includes pharmaceutical raw drugs and health materials Looking back at 2018, this year is called the policy year of the pharmaceutical industry For example, policies or regulations such as tax reduction for anticancer drugs, acceptance of overseas clinical trial data, acceleration of approval of imported drugs, centralized procurement of drugs in 4 + 7 cities, strict crackdown on fraudulent insurance documents, and the proposed catalogue of auxiliary drugs have a profound impact on the pharmaceutical industry In addition, in 2018, due to the stricter environmental protection and rising labor cost in China's pharmaceutical industry, a small number of API enterprises also engaged in malicious monopoly, resulting in a lack of product supply in many pharmaceutical manufacturing enterprises, and even the situation of production reduction and shutdown, which failed to achieve long-term maintenance of product output This is also one of the main reasons for the decline of capacity utilization in the pharmaceutical manufacturing industry throughout the year In terms of chemical pharmacy, according to the financial data of industrial enterprises released by the National Bureau of statistics on August 27, the export of chemical pharmaceutical preparations in China increased significantly from January to July, with a year-on-year increase of 44.5%, showing that the efforts of transformation and upgrading of domestic enterprises have achieved initial results, and the process of enterprise management and product quality in line with international standards has accelerated In terms of biopharmaceutical industry, data shows that the market scale of China's biopharmaceutical industry in 2017 is 218.5 billion yuan, and it is estimated that the market scale of China's biopharmaceutical industry in 2019 will exceed 300 billion yuan According to the industry, with the aging of the population, the increase of chronic diseases and the improvement of R & D and production capacity of China's biopharmaceutical companies, the biopharmaceutical industry showed a situation of "high opening and low going" in 2018, mainly due to the readjustment of valuation after the change of industry pattern and trend In the aspect of traditional Chinese medicine, according to the manufacturing process of traditional Chinese medicine, its typical product process is: Traditional Chinese medicine → Chinese herbal pieces → traditional Chinese medicine However, from the beginning of the process of traditional Chinese medicine, the lack of standardized management and scientific guidance in the planting areas of traditional Chinese medicine in 2018, the quality of traditional Chinese medicine varies, leading to frequent incidents of unqualified pieces of traditional Chinese medicine, which brings great trouble to the stable operation of the traditional Chinese medicine industry On August 31, 2018, the State Food and Drug Administration issued the notice on the work plan for the centralized treatment of the quality of Chinese herbal pieces to strictly inspect the illegal activities in the production, circulation and operation of Chinese herbal pieces, and to regulate the production of Chinese Herbal Pieces in a large frequency From the upstream to Chinese herbal medicine, the downstream to the Chinese medicine industry, all began to enter the period of strict supervision.